OncoMatch/Clinical Trials/NCT03425526
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Is NCT03425526 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes for hematopoietic and lymphoid cell neoplasm.
Treatment: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes — This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: corticosteroid (prednisone)
Exception: ≤ 0.1 mg/kg/day at time of enrollment
Patients receiving prednisone > 0.1 mg/kg/day or equivalent at time of enrollment
Cannot have received: anti-thymocyte globulin (ATG)
Exception: not received within 14 days
have received anti-thymocyte globulin (ATG) within 14 days
Cannot have received: donor lymphocyte infusion (DLI)
Exception: not received within 28 days
have received donor lymphocyte infusion (DLI) within 28 days of enrollment
Cannot have received: anti-CD52 antibody (Campath)
Exception: not received within 28 days
have received Campath within 28 days of enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify